Chronic obstructive pulmonary disease with mild airflow limitation: current knowledge and proposal for future research – a consensus document from six scientific societies [Corrigendum]
Authors Rossi A , Butorac-Petanjek B, Chilosi M, Cosío BG , Flezar M, Koulouris N , Marin J, Miculinic N , Polese G, Samaržija M, Skrgat S , Vassilakopoulos T, Vukić-Dugac A , Zakynthinos S, Miravitlles M
Received 13 November 2018
Accepted for publication 13 November 2018
Published 18 January 2019 Volume 2019:14 Pages 247—248
Rossi A, Butorac-Petanjek B, Chilosi M, Cosío BG, Flezar M, Koulouris N, Marin J, Miculinic N, Polese G, Samaržija M, Skrgat S, Vassilakopoulos T, Vukić-Dugac A, Zakynthinos S, Miravitlles M. Int J Chron Obstruct Pulmon Dis. 2017;12: 593–2610.
Page 2604, Disclosure, the text “The authors report no conflicts of interest in this work” should read “BGC has received speaker fees from Chiesi, Novartis, Menarini, AstraZeneca, Esteve and Rovi; research grants from Chiesi and Boehringer; and served on advisory boards for Chiesi, Novartis, AstraZeneca and Esteve. MM has received speaker fees from Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, CSL, Behring, Grifols and Novartis; consultancy fees from Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratories Esteve, Mereo BioPharm, Verona Pharma, pH Pharma, Novartis and Grifols; and research grants from GlaxoSmithKline and Grifols. The authors report no other conflicts of interest in this work”.
Read the original article
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]